Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...

Watch live as Kemi Badenoch gives evidence to the UK Covid inquiry on Wednesday, 27 January. The inquiry will also hear from ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...